Article Details

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Consensus Rating of "Buy" from Analysts

Retrieved on: 2021-06-11 05:03:45

Tags for this article:

Click the tags to see associated articles and topics

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Consensus Rating of "Buy" from Analysts. View article details on HISWAI: https://www.marketbeat.com/instant-alerts/nasdaq-sgmo-consensus-analyst-rating-2021-06-2-3/

Excerpt

Acadian Asset Management LLC now owns 9,925 shares of the biopharmaceutical company's stock valued at $124,000 after buying an additional 3,240 ...

Article found on: www.marketbeat.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up